STAT Plus: Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned

By MATTHEW HERPER

SMITH COLLECTION/GADO/SIPA/AP

Despite concerns about LRRK2 inhibitors, Denali has argued that new data indicate its hypotheses about the medicines will hold up.

READ MORE